Trial · NCT07507968
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma
NCT07507968, Phase 2, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma. Trials, record NCT07507968. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07507968
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma
- NCT number
- NCT07507968
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 101 participants, estimated
- Lead sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Conditions
- Esophagogastric Adenocarcinoma
- Interventions
- Durvalumab
- First posted
- 2026-04-02
- Last updated
- 2026-04-02
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathological complete response (pCR) | Approximately 13 months after FPI | Pathological complete response (pCR) rate as assessed locally, corresponding to the ypT0N0M0 stage category. pCR is defined as the proportion of patients with pathological complete remission in the post-surgery specimen, meaning complete absence of viable tumor cells in the primary tumor and lymph nodes and no evidence of metastatic disease upon pathological examination. For example, a patient with ypT0N0 but with pathologically confirmed peritoneal involvement containing viable tumor cells will not be considered to have achieved pCR. |
| Secondary | Event-free survival (EFS) plus EFS-rate at 1 year | Approximately 13 months after FPI | Event-free survival (EFS) plus EFS-rate at 1 year, defined as the time from enrollment until the date of one of the following events (whichever occurs first): progression acc. RECIST 1.1 that precludes surgery or requires non-protocol therapy during the neoadjuvant period; progression acc. RECIST 1.1 or recurrence during the adjuvant period; non-RECIST progression that precludes surgery or requires non-protocol therapy during the neoadjuvant period or discovered during surgery; progression/recurrence confirmed by biopsy post-surgery; or death due to any cause. Patients without an event at the time of data cut-off will be censored at the date of last disease assessment. |
| Secondary | Event-free survival (EFS) plus EFS-rate at 2 years | Approximately 26 months after FPI | Event-free survival (EFS) plus EFS-rate at 2 years, defined as the time from enrollment until the date of one of the following events (whichever occurs first): progression acc. RECIST 1.1 that precludes surgery or requires non-protocol therapy during the neoadjuvant period; progression acc. RECIST 1.1 or recurrence during the adjuvant period; non-RECIST progression that precludes surgery or requires non-protocol therapy during the neoadjuvant period or discovered during surgery; progression/recurrence confirmed by biopsy post-surgery; or death due to any cause. Patients without an event at the time of data cut-off will be censored at the date of last disease assessment. |
| Secondary | Rate of patients who undergo surgery (with or without resection) | Approximately 13 months after FPI | Number of patients who were surgically resected. |
| Secondary | R0 resection rate | Approximately 13 months after FPI | R0 resection rate, defined as proportion of patients in whom the surgical margin is microscopically negative for residual tumor |
| Secondary | Assessment of postoperative ypTNM stage | Approximately 13 months after FPI | Description of ypTNM stage after surgery as assessed locally |
| Secondary | Overall survival (OS) plus OS-rate at 2 years | Approximately 26 months after FPI | Overall survival (OS) plus OS-rate at 2 years, defined as time from enrollment to date of death due to any cause. Patients without an event at the time of data cut-off will be censored at the last known date alive |
| Secondary | QoL change from baseline | Approximately 36 months after FPI | QoL change from baseline, assessed using the EORTC QLQ-C30 questionnaire based on a four-point scale. A high scale score represents a higher response level and thus a worse outcome. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07507968
GET https://conductscience.org/api/trials/v1/NCT07507968/registered